Cargando…
Targeting Acute Myeloid Leukemia Stem Cells Through Perturbation of Mitochondrial Calcium
We previously reported that acute myeloid leukemia stem cells (LSCs) are uniquely reliant on oxidative phosphorylation (OXPHOS) for survival. Moreover, maintenance of OXPHOS is dependent on BCL2, creating a therapeutic opportunity to target LSCs using the BCL2 inhibitor drug venetoclax. While veneto...
Autores principales: | Sheth, Anagha Inguva, Engel, Krysta, Tolison, Hunter, Althoff, Mark J, Amaya, Maria L., Krug, Anna, Young, Tracy, Pei, Shanshan, Patel, Sweta B., Minhajuddin, Mohammad, Winters, Amanda, Miller, Regan, Shelton, Ian, St-Germain, Jonathan, Ling, Tianyi, Jones, Courtney, Raught, Brian, Gillen, Austin, Ransom, Monica, Staggs, Sarah, Smith, Clayton A., Pollyea, Daniel A., Stevens, Brett M., Jordan, Craig T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10592899/ https://www.ncbi.nlm.nih.gov/pubmed/37873284 http://dx.doi.org/10.1101/2023.10.02.560330 |
Ejemplares similares
-
PB1761: PRECLINICAL EVALUATION OF THE MENIN INHIBITOR ZIFTOMENIB IN PRIMARY AML SPECIMENS
por: Stevens, Brett, et al.
Publicado: (2023) -
4353 The Role of BCL2 Mediated Calcium Signaling on Leukemia Stem Cell Metabolism
por: Inguva, Anagha, et al.
Publicado: (2020) -
Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia
por: Cherry, Evan M., et al.
Publicado: (2021) -
Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia
por: Gutman, Jonathan A., et al.
Publicado: (2023) -
LABRAT reveals association of alternative polyadenylation with transcript localization, RNA binding protein expression, transcription speed, and cancer survival
por: Goering, Raeann, et al.
Publicado: (2021)